1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,620 | 4,060 | 10:04 | |
| 3,960 | 4,120 | 28.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Cytek Biosciences: Teilsieg im Patentstreit - dennoch 56 Millionen US-Dollar Schadenersatz | 2 | Investing.com Deutsch | ||
| 21.08. | Cytek Biosciences wins on three of four patent claims | 3 | Investing.com | ||
| 21.08. | Cytek Biosciences, Inc.: Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding | 473 | GlobeNewswire (Europe) | FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (Nasdaq: CTKB), a leading cell analysis solutions company, today announced... ► Artikel lesen | |
| 12.08. | Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments | 2 | pulse2.com | ||
| 06.08. | Cytek raises 2026 revenue outlook to $207M-$212M as it rolls out Borealis and Aurora Evo automation | 2 | Seeking Alpha | ||
| 05.08. | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| CYTEK BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 22.07. | Cytek Biosciences, Inc.: Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 15.07. | Cytek Biosciences, Inc.: Cytek Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement | 1 | GlobeNewswire (USA) | ||
| 15.07. | Cytek Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | Cytek Biosciences, Inc.: Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026 | 1 | GlobeNewswire (USA) | ||
| 02.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Earnings Call Transkript: Cytek Biosciences meldet Umsatzwachstum für Q1 2026, verfehlt aber Gewinnprognose | 1 | Investing.com Deutsch | ||
| 13.05. | Stephens cuts Cytek Biosciences stock price target on elevated costs | 1 | Investing.com | ||
| 13.05. | Cytek Biosciences: Stephens senkt Kursziel wegen hoher Kosten | 1 | Investing.com Deutsch | ||
| 08.05. | Cytek reaffirms $205M-$212M 2026 revenue outlook as U.S. growth rebounds | 5 | Seeking Alpha | ||
| 07.05. | Cytek Biosciences GAAP EPS of -$0.15 misses by $0.05, revenue of $44.1M misses by $0.2M | 2 | Seeking Alpha | ||
| 07.05. | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,006 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| BIOFRONTERA | 2,500 | +2,46 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| CLINUVEL | 5,318 | -0,26 % | Clinuvel Pharmaceuticals Ltd - 6-K, Report of foreign issuer | ||
| EDITAS MEDICINE | 2,750 | +0,73 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,680 | +1,20 % | B.Riley stuft Cardiol Therapeutics mit Kauf ein: Kursziel impliziert über 400 % Potenzial | ||
| ASEP MEDICAL | 0,055 | 0,00 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,520 | -0,40 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,840 | +4,02 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| CYTODYN | 0,192 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,958 | -2,88 % | Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3... ► Artikel lesen | |
| DENALI THERAPEUTICS | 20,870 | +0,72 % | Denali Therapeutics Inc.: Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million | Proceeds from transaction to support advancement of Denali's broad TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority... ► Artikel lesen | |
| CEL-SCI | 1,310 | +1,55 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,215 | 0,00 % | Coherus Oncology, Inc. - 8-K, Current Report | ||
| CURIS | 1,462 | +14,43 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,074 | 0,00 % | Fate Therapeutics, Inc.: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis | First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated... ► Artikel lesen |
CYTEK BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +5,95 % bei einem Aktienkurs von 3,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTEK BIOSCIENCES INC finden Sie auf Wallstreet Online.